Sector: Life Sciences

Latest content

Disentangling the problem of patent thickets

The Long Read: Biosimilars face far larger patent estates in the US than elsewhere. But when considering the causes of – and potential remedies for – the country’s thicketing phenomenon, the problem turns out to be a thorny one

06 October 2021

Revolutionise your patent process to maximise innovator value, urges GE Research IP chief

Buck de Wolf explains how he overcame his own and others’ scepticism to secure a change of approach that has paid considerable dividends

05 October 2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

US federal court victory sets up the $13.4 billion drug for exclusivity until 2028

05 October 2021

IP concerns appear low on Biden administration’s China agenda

Remarks by US Trade Representative Katherine Tai outlining new US approach to China almost entirely neglect IP issues that were the centrepiece of Trump 301 investigation

05 October 2021

Expect a dramatic finale to the Humira patent saga

Saturday Opinion: Alvotech’s speedy infringement trial could see its product jump the queue of adalimumab biosimilars in the final months before AbbVie’s exclusivity comes to an end

02 October 2021

Biopharma IP licensors are getting more money - and earlier - for their innovations

M&A may be stagnant, but innovators are receiving larger upfront payments for partnership agreements

01 October 2021

What patent owners need to know about financing life sciences disputes

The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals

29 September 2021

How expedition is changing Australian pharma patent disputes

A growing trend in life sciences litigation Down Under has strategic implications for originators and generics/biosimilars alike

28 September 2021

The battle over Leahy’s PTAB reforms begins

Provisions in the proposed legislation to undo discretionary denials of IPRs stoke most discussion, with some alleging Big Tech is the main beneficiary

24 September 2021

Moderna’s covid-19 IP pledge is about to be put to the test

The WHO’s African vaccine hub is seeking to imitate the company’s jab, but an agreement has yet to be reached

24 September 2021

Get unlimited access to all IAM content